Precision Medicine Group

Today is the 10th International Day of Women and Girls in Science. Even as we cheer women’s leadership in STEM (science, technology, engineering, math), we recognize that there is still a long path to parity: women have fewer STEM jobs, have less seniority, and receive smaller research grants. That must change. As increasing numbers of women enter the STEM fields, they bring fresh perspectives, critical talents, and creative approaches to some of today’s greatest challenges. Join Precision in celebrating the women who are leading scientific innovation—and in calling for the removal of all barriers to their progress. #WomenInScience #WomenInSTEM #STEM

We loved keeping it cool as a sponsor of the Polar Lounge at the annual Fire In Ice event in Frederick, MD this past weekend. The live ice carving and pyrophoric fire performances are always a hit! Frederick is home to one of our world-class labs and we're proud to be part of the community and support great events such as Fire In Ice. https://lnkd.in/eukMGw7U

The industry is moving forward with confidence, and key investments are setting the stage for a big year in biomanufacturing. In this edition of our Precision Manufacturing newsletter, Adam Pfeiffer breaks down the latest biomanufacturing headlines, from mRNA advancements to gene therapy breakthroughs and large-scale facility expansions. Click below to read the full article and subscribe to our newsletter today. #Biotech #Biomanufacturing #PharmaInvestments #mRNA

Sentiment from experts across the industry is clear – biotech is pushing forward with confidence! In this episode of Manufacturing Milestones, Adam Pfeiffer, VP of Strategy at Project Farma (PF), breaks down the latest major investments and what they mean for biomanufacturing. Unmute to hear Adam discuss: • Moderna’s $590M mRNA investment • Children’s Hospital of Los Angeles expanding gene therapy • Amgen’s $1.5B expansion in Holly Springs What biotech manufacturing developments are you watching? #Biotech #Biomanufacturing #GeneTherapy #PharmaInvestments

Every cancer story is unique—and every cancer story reflects the unique person at its heart. That’s why personalized cancer care is so critical. Today, as we honor World Cancer Day, Precision joins the call to make people-centered cancer care a reality across the globe. Then, together, we will celebrate victories in the fight against cancer. #WorldCancerDay #UnitedByUnique #Cancer #CancerAwareness

Real-time sample intelligence isn't just a buzzword. AI is making it a reality. Curious? Catch Tobias Guennel TODAY at 12:35pm at the #SCOPESummit with his session: “From Site to Result: Real-Time Sample Intelligence Unlocked with GenAI”. He'll cover how you can use AI to ask questions, get answers, and gain insights across the entire precision medicine data value chain, with real-time sample intelligence from point of collection to data generation. ➡️ Check out the details and add it to your agenda: https://lnkd.in/eHtumvyf #ClinicalOperations #ClinicalResearch #SCOPESummit

A single misstep in slot assignment can derail an entire study. This webinar will cover proven frameworks for cohort planning, patient enrollment, and effective dose optimization—so your trials stay on track. Save your seat: https://lnkd.in/gUwT2qTJ

Today, as Black History Month begins, Precision honors 2 pioneering Black doctors whose work advances women’s health. Our gratitude to Dr. Dorothy Celeste Boulding Ferebee (1898–1980) for the foundational work she did and to Dr. Ndidiamaka Amutah-Onukagha, founder of the Center for Black Maternal Health and Reproductive Justice (CBMHRJ), who continues the fight. #BlackHistoryMonth #TrailblazingHealthcare #MaternalHealth

New Pink Sheet article on how new FDA guidance offers more clarity around the timing of confirmatory trials. Precision CMO Harpreet Singh, MD was interviewed for the article to discuss the implications of the latest guidance: “I think a lot of people are restrategizing around should they even go for an accelerated approval first, or should they go straight to a registrational trial that’s for a regular approval like a randomized design,” Singh said. “I think it’s a little bit turning drug development on its head, and I don’t necessarily think it’s a good thing in every circumstance.” Here's a link to the full article and more on the topic from Harpreet (note that a subscription is required): https://lnkd.in/esr8gBUC

Watch Chad Clark, President and COO of Precision Medicine Group, share 4 key takeaways from the JP Morgan conference in this 2 ½ minute interview. Hear his take on a renewed optimism and a key shift in the conference that is benefiting biotech.